Human immunodeficiency virus tat-activated expression of poliovirus protein 2A inhibits mRNA translation by Sun, Xiao-Hong & Baltimore, David
mRNA Translation
Human Immunodeficiency Virus Tat-Activated Expression of Poliovirus Protein 2A Inhibits
Xiao-Hong Sun, and David Baltimore 
doi:10.1073/pnas.86.7.2143 
 1989;86;2143-2146 PNAS
 This information is current as of December 2006.
 www.pnas.org#otherarticles
This article has been cited by other articles: 
 E-mail Alerts
. click herethe top right corner of the article or
Receive free email alerts when new articles cite this article - sign up in the box at
 Rights & Permissions
 www.pnas.org/misc/rightperm.shtml
To reproduce this article in part (figures, tables) or in entirety, see: 
 Reprints
 www.pnas.org/misc/reprints.shtml
To order reprints, see: 
 Notes:
Proc. Nati. Acad. Sci. USA
Vol. 86, pp. 2143-2146, April 1989
Biochemistry
Human immunodeficiency virus tat-activated expression of
poliovirus protein 2A inhibits mRNA translation
(trans-activation/protein synthesis/protease)
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Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142; and Department of Biology, Massachusetts Institute of Technology,
Cambridge, MA 02139
Contributed by David Baltimore, December 19, 1988
ABSTRACT To study the effect ofpoliovirus protein 2A on
cellular RNA translation, the tat control system of human
immunodeficiency virus (HIV) was used. Protein 2A was
expressed from a plasmid construct (pHIV/2A) incorporating
the HIV long terminal repeat. Protein synthesis was measured
by using chloramphenicol acetyltransferase as a reporter gene
driven by the Rous sarcoma virus long terminal repeat. When
HIV/2A was cotransfected with the reporter, addition of a
tat-producing plasmid caused at least a 50-fold drop in chlor-
amphenicol acetyltransferase synthesis. A HeLa cell line car-
rying HIV/2A was established. In it, tat expression caused
more than a 10-fold drop in chloramphenicol acetyltransferase
synthesis from the reporter plasmid. Furthermore, 2A induc-
tion by tat caused cleavage of the cellular translation factor
P220, a part ofeukaryotic translation initiation factor 4F. Thus
protein 2A can, by itself, carry out the inhibition of cellular
protein synthesis characteristic of a poliovirus infection. Also,
the HIV tat activation provides a very effective method to
control gene expression in mammalian cells.
Poliovirus causes a dramatic shutoff of host cell mRNA
translation within several hours after infection (1). The
mechanism of shutoff is thought to be inactivation of eukary-
otic translation initiation factor 4F (eIF-4F) (2). Poliovirus
induces the cleavage of the P220 component of eIF-4F (3), a
factor that assists the binding of capped mRNAs to the 40S
ribosome as part of the translation initiation process (4). The
virus's strategy thus appears to be to prevent the cap-
dependent translation initiation used by cellular mRNAs,
while allowing the cap-independent translation of polioviral
RNA.
Poliovirus protein 2A is a protease whose mature form is
generated by the cleavage of the precursor polyprotein of
poliovirus at its N terminus by 2A itself (5) and at the C
terminus by another protease, 3C (6). In addition to its
cleavage function, 2A also appears to be involved in the
shutoff of cellular protein synthesis, because an insertion in
the protein 2A yields a small-plaque mutant virus defective in
the shutoff (7). Infection with such mutant virus also fails to
induce the cleavage of P220 (7), which occurs during wild-
type virus infection as well as in HeLa cell extracts in the
presence of in vitro-translated 2A protein (8). We have used
the human immunodeficiency virus type 1 (HIV-1) long
terminal repeat (LTR) as a controlling element for expression
of protein 2A in HeLa cells and found that 2A by itself
dramatically inhibits cellular mRNA translation. We also
detected cleavage of P220 following 2A expression. Addi-
tionally, we have shown that the LTR of HIV-1 and its
trans-activator (tat protein) can act as an effective, controlled
expression system.
MATERIALS AND METHODS
Plasmids. The structures of the plasmids are shown in Fig.
1. To generate pHIV/2A, a BstEII fragment (nucleotides
3235-3930) from a poliovirus cDNA (9) was filled in with
DNA polymerase (Klenow fragment), attached to a 12-mer
EcoRI linker, and then inserted into the EcoRI site of the
chloramphenicol acetyltransferase (CAT) gene driven by
HIV-1 LTR in a plasmid, called 933A (a gift of Sunyoung
Kim, Whitehead Institute for Biomedical Research). This
fragment is in-frame with the CAT gene at its N terminus, but
out-of-frame at its C terminus, which creates a stop codon
following 9 random amino acids. Thus, the coding sequence
of the fusion gene contains 73 N-terminal amino acids of
CAT, the polioviral sequence including 50 C-terminal amino
acids of region P1, the entire 2A, and 33 N-terminal amino
acids of protein 2B, and the 9 random amino acids. In the
transcription unit of pHIV/2A, between the stop codon and
the simian virus 40 (SV40) polyadenylylation site, are a 3'
portion ofthe CAT gene, 900 base pairs oftruncated envelope
sequence of HIV-1, and the intervening sequence of SV40
(not indicated in Fig. 1). pHIV/2A-1 was constructed by
replacing the BstEII fragment in pHIV/2A with the BstEII
fragment from the 2A-1 mutant cDNA (7, 10). To generate the
deletion in 2A ofpHIV/2APX, we digested HIV/2A plasmid
with Xba I (nucleotide 3581 in the poliovirus sequence) and
filled in the Xba I site. This linear DNA was then partially
digested with Pst I, and the fragment that was digested only
at the Pst I site in the poliovirus sequence (nucleotide 3420)
was selected by using a 1% low-melting-point agarose gel.
The two ends of this fragment were ligated with a polylinker
fragment with a Pst I end on one side and a blunt end on the
other, which was isolated from the Bluescript plasmid (Strat-
agene) by digesting with Pst I and EcoRV.
In Viro Transcription and Translation. To synthesize
RNAs in vitro, the HindIII-BgJ II fragments (Fig. 1) con-
taining the coding sequences of the fusion proteins were
excised from HIV/2A, HIV/2A-1, and HIV/2APX and
ligated to the HindIII and BamHI sites of SP64 (Promega). A
HindIII-BglII fragment containing the CAT reading frame
was also cloned into SP64 to synthesize a control template.
The coding strands were synthesized with SP6 polymerase
(Promega). Approximately 1 pxg ofRNA was used for the in
vitro translation in 50 .14 of the nuclease-treated rabbit
reticulocyte lysate (Promega) containing [35S]methionine ac-
cording to the vendor. Five microliters of each reaction mix
was diluted in 1 ml of immunoprecipitation buffer (20 mM
Tris'HCl, pH 7.5/1% Triton X-100/0.5% sodium deoxycho-
late/0.1% SDS/1 mM EDTA) and centrifuged at 40,000 rpm
in an SW50.1 rotor (Beckman) for 30 min. The supernatants
were immunoprecipitated with an anti-2A serum and Staphy-
Abbreviations: HIV, human immunodeficiency virus; CAT, chlor-
amphenicol acetyltransferase; LTR, long terminal repeat; eIF, eu-
karyotic initiation factor; SV40, simian virus 40.
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FIG. 1. Construction of the HIV/2A gene and derivatives. A
restriction map of HIV/2A is shown at the top. The LTR of HIV-1
is boxed. The coding sequence ofHIV/2A or its derivatives is shown
by the second box, in which the CAT sequence, the polioviral
sequence, and random amino acids are represented by the hatched,
stippled, and solid black portions, respectively. The region in the
polioviral sequence encoding 2A is bracketed underneath. Thejunction of P1 and 2A is marked by an inverted triangle. The
remainder of the sequences are shown with a thin line, and the SV40
polyadenylylation site is indicated. kb, Kilobase.
lococcus aureus protein A-positive cells (Boehringer Mann-
heim). Portions ofthe supernatants and pellets were analyzed
by electrophoresis through a SDS/20% polyacrylamide gel.
Transfection of HeLa Cells and Establishing Cell Lines.
HeLa cells were plated in Dubecco's modified Eagle's
medium containing 10% fetal calf serum at about 5 x 105 cells
per 60-mm Petri dish 12-24 hr prior to transfection. The
calcium phosphate/DNA precipitates were prepared as de-
scribed (11) and applied to cells without the medium and
incubated at 25°C for 15 min before addition of fresh medium.
Glycerol shock was performed 12 hr after the addition of
precipitates. Cells were harvested 48 hr after the addition of
precipitates, and CAT activities were assayed as described
(12). The HeLa 2A-38 cell line was established by cotrans-
fecting pHIV/2A with pSV2neo (13) by using the calcium
phosphate/DNA precipitate method. Transfected cells were
selected 48 hr later with G418 at 1 mg/ml in Dulbecco's
modified Eagle's medium for 2 weeks. About 50 individual
colonies were propagated for analyzing their genomic struc-
tures and the inhibitory function of 2A.
Protein Immunoblot. An immunoblot experiment was per-
formed with an antiserum against P220, essentially as de-
scribed by Bernstein et al. (7) except that an alkaline
phosphatase-conjugated anti-rabbit IgG (Promega) was used
as the second antibody as described by the vendor.
RESULTS
Constructs Expressing 2A Under the Control of HIV LTR.
To express the poliovirus protein 2A in cells, we constructed
a plasmid, pHIV/2A, by fusing a 695-base-pair BstEII frag-
ment from a poliovirus cDNA (Mahoney strain) in frame with
the coding sequence of a CAT gene, whose expression is
under the control of the HIV-1 LTR (Fig. 1). We also
constructed similar fusion genes, pHIV/2A-1 and pHIV/2-
APX, with mutations in the 2A sequence (Fig. 1). pHIV/2A-1
contains a single amino acid insertion in 2A, which results in
a mutant poliovirus, 2A-1, that is defective in shutting off host
cell protein synthesis upon infection (7, 10). pHIV/2APX has
a 53-amino acid deletion in 2A.
Proper Processing of the 2A Fusion Proteins. Because 2A,
which has a proteolytic activity, is known to cleave the
junction between P1 and itself (5), we expected that the
predicted 41-kDa fusion protein from the constructs would be
processed by 2A, resulting in a mature protein of 24.5 kDa
containing only 2A and a small part of 2B. We demonstrated
such processing by examining the in vitro-translated products
from the coding sequences of the fusion proteins in various
constructs. The RNA containing the coding sequence of
pHIV/2A directed synthesis of a 24.5-kDa protein (Fig. 2a,
lane 3) that was immunoprecipitated by anti-2A serum (Fig.
2b, lane 3). The coding sequence should direct synthesis of a
41-kDa protein, but processing is apparently so complete that
none is left; the 17-kDa P1 cleaved polypeptide was not
detected and may have been degraded. The partially defec-
tive mutant 2A-1 gave rise to 24.5-kDa and 41-kDa products,
both of which reacted with anti-2A serum (Fig. 2, lanes 4),
implying that mutant 2A-1 is defective in cleavage of 2A from
its precursor and confirming that a 41-kDa product is made
from the construct. In pHIV/2APX, the 53-amino acid
deletion caused synthesis of a major 33-kDa immunoprecip-
itable product (Fig. 2, lanes 5). The minor 27-kDa product is
presumed to result from alternative initiation from an in-
frame AUG or could be an aberrant nonspecific cleavage
product. Specific cleavage at the P1/2A junction would have
generated a much smaller product. Thus, the constructs
produce the predicted products, implying that 2A is prote-
olytically active and that the mutants partially or completely
block specific cleavage.
Effects of 2A on Cellular mRNA Translation. We then
examined the ability of 2A to inhibit cellular mRNA trans-
lation by cotransfection experiments. The plasmids used
were a reporter construct, pRSVCAT (14), in which the CAT
gene is controlled by the LTR of Rous sarcoma virus;
pHIV/2A, expressing poliovirus protein 2A; and pSVETA,
in which the HIV-1 tat gene is transcribed from an SV40
promoter (15), providing trans-activator function (Fig. 3c).
We expected that pHIV/2A would need tat synthesis from
pSVETA for expression of the 2A protein because the HIV
LTR is strongly controlled by tat (15). We also expected that
the expression of 2A would inhibit the translation of pRSV-
CAT mRNA and give a low CAT activity (Fig. 3c). These
expectations were fulfilled: the expression of tat greatly
decreased synthesis of CAT when cells were cotransfected
with pRSVCAT and pHIV/2A (Fig. 3a, compare lanes 3 and
4). Without pHIV/2A, no inhibition was evident (Fig. 3a,
lanes 1 and 2). The single amino acid insertion in 2A greatly
impaired the ability of 2A to inhibit mRNA translation (Fig.
3a, lanes 5 and 6), whereas a deletion in 2A completely
abolished its inhibitory function (Fig. 3a, lanes 7 and 8). In
addition, we performed similar cotransfection experiments
with a pRSVLacZ plasmid (the P-galactosidase gene driven
by the LTR of Rous sarcoma virus) (16) or a pSV2CAT
a
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FIG. 2. In vitro translation of the 2A and 2A mutant fusion
proteins. (a) Total translation products. (b) Immunoprecipitation.
RNAs used for translation contain the coding sequences of mock
(lane 1), CAT (lane 2), 2A (lane 3), 2A-1 (lane 4), and 2APX (lane 5).
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FIG. 3. The inhibitory effect of 2A on mRNA translation. (a) HeLa cells were cotransfected with equal molar amounts of pRSVCAT and
either pSVETA or carrier DNA as indicated plus carrier DNA (lanes 1 and 2), pHIV/2A (lanes 3 and 4), pHIV/2A-1 (lanes 5 and 6), and
pHIV/2APX (lanes 7 and 8). CAT activities were measured and expressed as the percentage of conversion from chloramphenicol (CM) to
acetylated chloramphenicol (AC). (b) In the HeLa 2A-38 cell line, 10 /ig of pRSVCAT was cotransfected with or without 10 ,ug of pSVETA,
and CAT activities were determined. The above experiments have been repeated at least three times, and similar results were obtained. (c)
Rationale of the experimental design.
plasmid (the CAT gene driven by SV40 early promoter) (12)
as the reporter genes and obtained equivalent results (data
not shown), suggesting that the inhibition oftranslation by 2A
is not specific to a particular protein, promoter, or mRNA
capping sequence. Thus, we conclude that 2A, even when it
is expressed out of the context of poliovirus, inhibits cellular
mRNA translation. It probably will kill cells, although that is
not demonstrated here.
Establishment ofthe Cell Lines Carrying HIV/2A Gene. The
low level of expression from the LTR of HIV-1 without tat
expression allowed us to establish HeLa cell lines perma-
nently carrying pHIV/2A. The plasmid pHIV/2A was co-
transfected into HeLa cells with the plasmid pSV2neo, which
expressed the neomycin-resistance gene (13). Several dozen
individual neomycin-resistant colonies were obtained. The
expression of the integrated HIV/2A genes could then be
activated by transfecting in the tat gene expressed by
pSVETA. The inhibitory function of2A in these cell lines was
assayed by cotransfecting pRSVCAT and pSVETA and
measuring the CAT activity of the cotransfected extracts.
These cell lines were found to contain variable copies of
HIV/2A genes and respond to tat activation to variable
extents. One of the cell lines, 2A-38, carried 10-20 copies of
the HIV/2A gene and translated RSVCAT mRNA more than
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FIG. 4. The cleavage of P220 in 2A-producing cells. Immunoblot
experiment was performed with an antiserum against P220. Extracts
were prepared 48 hr posttransfection from HeLa cells transfected
with or without pSVETA (lanes 1 and 2) and 2A-38 cells transfected
with or without pSVETA (lanes 3 and 4). Extracts were also prepared
from HeLa cells infected with wild-type (lane 6) or 2A-1 mutant virus
(lane 5) at multiplicity of infection of 20 for 3.5 hr. One-fifth of the
extracts from each 60-mm dish was analyzed by electrophoresis
through a SDS/6.5% polyacrylamide gel. P220 and its cleavage
products (c.p.) are indicated.
10 times less efficiently when pRSVCAT was cotransfected
with pSVETA compared to transfection without pSVETA
(Fig. 3b).
Cleavage of P220 by 2A Expression in Vivo. During polio-
virus infection, not only is host cell protein synthesis shut off,
but also the polypeptide P220, a component of eIF-4F, is
cleaved (3). Poliovirus protein 2A also appears to be involved
in this cleavage event, both because mutant 2A-1 fails to
trigger the cleavage of P220 (7) and because in vitro-
translated 2A indirectly induces the cleavage of P220 in a
HeLa cell extract (8). We therefore investigated if 2A, when
expressed alone in vivo, could cause the cleavage ofP220. We
activated the expression of 2A in the cell line 2A-38 by
transiently transfecting it with the tat gene and assayed the
cleavage products of P220 in the transfected extract by an
immunoblot using an anti-P220 serum. The cleavage products
were apparent in the induced 2A-38 cells (Fig. 4, lane 3) but
not in either the unactivated 2A-38 cells (lane 4) or normal
HeLa cells (Fig. 4, lanes 1 and 2). The cleaved products
comigrated with those in poliovirus-infected HeLa cells (Fig.
4, lane 6). Due to the inefficiency of the calcium phosphate/
DNA precipitate transfection method, only a portion of the
2A-38 cells used for transfection would be expected to
receive the tat gene, express 2A, and induce the cleavage of
P220. Thus, in Fig. 4, lane 3, the cleavage products were
probably contributed from this portion of the cells, whereas
the intact P220 would be from the remaining portion that did
not receive the tat gene. Fig. 4, lane 4 also emphasizes that
in 2A-38 cells the baseline expression of2A protein is so low
that no cleavage of P220 is detectable.
DISCUSSION
It was previously evident that a mutant in protein 2A
interferes with the virus-induced shutoff of host cell protein
synthesis (7). It was also, evident that 2A is a protease that
cleaves the P1-2A bond in the poliovirus polyprotein (5).
Because protein 2A is cleaved from precursors, it was not
clear that 2A itself was responsible for both effects. The
present results show directly that expression of 2A (with a
short tail of 2B attached) can cause inhibition of cellular
mRNA translation. 2A also acts as a protease, since 2A
mutants are defective in cleavage of 2A from its precursor.
2A is able to induce cleavage of P220, as was also evident
from in vitro results (8), but the mechanism of cleavage,
thought to be an indirect effect of 2A (8), remains obscure.
Unlike most other retroviruses, the LTR of HIV can be
transactivated several hundred-fold by the tat gene from a
very low basal level (15, 17). The level of expression in HeLa
a
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cells after activation is much higher than synthesis from Rous
sarcoma virus LTR or SV40 early promoter. We have shown,
by our success in establishing cell lines carrying the HIV/2A
gene, that this feature of the HIV LTR can be utilized as a
good activatable system to study the functions of proteins
toxic to cells. On the other hand, this feature can also be
utilized to design strategies that might counter HIV infection.
For example, by introducing the HIV/2A gene into cells
before or after HIV infection, we could specifically kill the
infected cells and prevent further infection of normal cells.
We thank Jing-po Li, Didier Trono, and Raul Andino for sugges-
tions, Nahum Sonenberg for the anti-P220 serum, and Sunyoung Kim
for the HIV/CAT plasmid. This work was supported by grants from
the National Institute of Allergy and Infectious Diseases and the
National Institute of General Medical Sciences.
1. Baltimore, D. (1969) in The Biochemistry ofPicornaviruses, ed.
Levy, H. (Dekker, New York), pp. 101-176.
2. Sonenberg, N. (1987) Adv. Virus Res. 33, 175-204.
3. Etchison, D., Milburn, S., Edery, I., Sonenberg, N. & Her-
shey, J. W. (1982) J. Biol. Chem. 257, 14806-14810.
4. Shatkin, A. (1985) Cell 40, 223-224.
5. Toyoda, H., Nicklin, M. J. H., Murry, M. G. & Wimmer, E.
(1986) Cell 45, 761-770.
6. Hanecak, R., Semler, B. L., Anderson, C. W. & Wimmer, E.
(1982) Proc. Natl. Acad. Sci. USA 79, 3973-3977.
7. Bernstein, H. D., Sonenberg, N. & Baltimore, D. (1985) Mol.
Cell. Biol. 5, 2913-2923.
8. Krausslich, H. G., Nicklin, M. J. H., Toyoda, H., Etchison,
D. & Wimmer, E. (1987) J. Virol. 61, 2711-2718.
9. Racaniello, V. R. & Baltimore, D. (1981) Proc. Natl. Acad. Sci.
USA 78, 4887-4891.
10. Bernstein, H. D., Sarnow, P. & Baltimore, D. (1986) J. Virol.
60, 1040-109.
11. Sun, X.-H., Lis, J. T. & Wu, R. (1988) Genes Devel. 2, 743-
753.
12. Gorman, C. M., Moffat, L. F. & Howard, B. H. (1982) Mol.
Cell. Biol. 2, 1044-1051.
13. Southern, P. & Berg, P. (1982) J. Mol. Appl. Genet. 1, 327-341.
14. Gorman, C. M., Merlino, G. T., Willingham, M. C., Pastan, I.
& Howard, B. H. (1982) Proc. Natl. Acad. Sci. USA 79,
6777-6781.
15. Muesing, M. A., Smith, D. H. & Capon, D. J. (1987) Cell 48,
691-701.
16. Hall, C. V., Jacob, P. E., Ringold, G. M. & Lee, F. (1983) J.
Mol. Appl. Genet. 2, 101-109.
17. Sodroski, J., Rosen, C., Wong-Staal, F., Salahuddin, S. Z.,
Popovic, M., Arya, S., Gallo, R. C. & Haseltine, W. A. (1985)
Science 227, 171-173.
Proc. Natl. Acad. Sci. USA 86 (1989)
